Bodor Laboratories, Inc.

Auxilium US Holdings, LLC

University of Texas System

Applied Molecular Transport Inc.

Lung Therapeutics, Inc.

Rein Therapeutics, Inc.

Phoenix Biotechnology, Inc.

Epicept Corporation

Recro Pharma, Inc.

Baudax Bio, Inc.

Auxilium International Holdings, Inc.

John Joseph Koleng, Jr

Nicholas S Bodor

David Angulo

Feng Zhang

Michael Crowley

Justin M Keen

Dale Christensen

Robert O Williams, Iii

Sean Dalziel

Randall J Mrsny

Tahir Mahmood

Derek Maclean

Alan B Watts

Marvin R Garovoy

Sally Rhiannon Postlethwaite

Weijun Feng

Randall J Mack

Geraldine A Henwood

Christopher T Sharr

Yajie Zhang

Kevin Yin

Bittoo Kanwar

Hyojin Kim

Rajendra Tandale

Sawittree Sahakijpijarn

Michael M Crowley

Otis Crandell Addington

Gavril W Pasternak

Sreerama Shetty

Yuri Kolesnikov

Charles A Freyer

Charles Alexander Freyer

Crandell Addington

Michael W Crowley

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Formulation for soft anticholinergic analogs

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Dry powder formulation of caveolin-1 peptides and methods of use thereof

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Compositions, formulations and interleukin production and purification

Growing community of inventors

Austin, TX, United States of America

John Joseph Koleng, Jr